556 related articles for article (PubMed ID: 9313044)
1. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant hormonal deprivation before radical prostatectomy.
Schulman CC; Sassine AM
Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
4. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
Villavicencio Mavrich H; Chéchile Toniolo G; Salinas Duffo D; Muñoz Plaza J; Sorraca Ibáñez YJ
Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
[TBL] [Abstract][Full Text] [Related]
6. Histopathological effects of androgen deprivation in prostatic cancer.
Civantos F; Soloway MS; Pinto JE
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
Andros EA; Danesghari F; Crawford ED
Clin Invest Med; 1993 Dec; 16(6):510-5. PubMed ID: 7516835
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
[TBL] [Abstract][Full Text] [Related]
10. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
12. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
Labrie F; Dupont A; Cusan L; Gomez J; Diamond P; Koutsilieris M; Suburu R; Fradet Y; Lemay M; Têtu B
Clin Invest Med; 1993 Dec; 16(6):499-509. PubMed ID: 8013155
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
14. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
15. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
16. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant hormonal therapy for prostate cancer].
Miyakita H
Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
19. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
20. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
Wieder JA; Soloway MS
J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]